Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotics Pipeline Is Lively, But Sponsors Are Fragile

Executive Summary

Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.

You may also be interested in...



US FDA Joins Chorus Of Concerns About Results Of GAIN Act

It's too early to say whether program is working, FDA tell Congress; agency has awarded 147 QIDP designations, but none of 12 approved antibacterals have new mechanism of action.

New Report Calls For Pushing And Pulling In Global Fight Against Superbugs

New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.

Antibiotic Spring? Regulatory Incentives Spur Activity – And Maybe Medical Advances

Regulatory incentives have been successful at attracting developers to antibiotic R&D, but significant medical advances have stubbornly remained rare. Now the pipeline has produced the first novel antibiotic to receive breakthrough status from US FDA and some Phase III trials are raising the efficacy bar to superiority.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC099050

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel